SAN DIEGO, April 12, 2016 /PRNewswire/ -- Sequenom,
Inc. (NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, is pleased to announce that Glenn
Magnuson has joined the Company as Vice President of Sales,
reporting to Rob Lozuk, Senior Vice
President, Commercial Operations. Mr. Magnuson has more than
25 years of experience in implementing effective sales processes,
strategically managing accounts and realizing the revenue potential
of medical diagnostic devices.
"I'm delighted to welcome Glenn to Sequenom's executive team,"
said Dirk van den Boom, Ph.D.,
President and CEO of Sequenom. "The three new tests we
launched in 2015 and our entry in the average-risk pregnancy market
provide Sequenom Laboratories with outstanding potential to expand
its market presence, both for noninvasive prenatal tests as well as
in carrier screening. Glenn's proven record of motivating
sales teams and facilitating long term business relationships in
medical diagnostics and women's health is exactly what Sequenom
Laboratories needs to expand its contribution to women's
healthcare."
"With the broadest array of laboratory-developed tests in the
industry, strong backing from maternal fetal medicine specialists,
and its knowledgeable and professional sales team, Sequenom
Laboratories is well-positioned to bring the benefits of
noninvasive prenatal testing to as many patients as possible,
including women with average-risk pregnancies," said Mr.
Magnuson. "My experience in medical diagnostics --
specifically including my background in women's health – is a great
fit with Sequenom Laboratories' growth potential in this
market."
Glenn Magnuson has 25 years of
medical diagnostic sales experience, including immunology sales at
Abbott Diagnostics; women's diagnostic tests at Cytyc / Hologic;
and clinical chemistry, hematology, pathology, and molecular and
point of care technologies at ThermoFisher Scientific. Most
recently, Mr. Magnuson was Vice President of Sales for T2
Biosystems, a leading provider of an FDA-approved Candida direct
whole blood sepsis test. He holds a Bachelor of Science
degree in Business Administration from Bryant
University in Rhode
Island.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a
pioneering genetic testing company dedicated to women's health
through the development of innovative products and services.
The Company serves patients and physicians by providing early
patient management information. For more information, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a
CAP-accredited and CLIA-certified molecular diagnostics laboratory,
has developed a broad range of laboratory tests, with a focus
principally on prenatal care. Branded under the names
HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME,
MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT™,
these molecular genetic laboratory-developed tests provide early
patient management information for obstetricians, geneticists, and
maternal fetal medicine specialists. Sequenom Laboratories is
changing the landscape in genetic diagnostics using proprietary
cutting edge technologies. Visit www.laboratories.sequenom.com and
follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service
marks are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 including statements regarding the development of
innovative products and services, the ability to expand the
Company's market presence for non-invasive prenatal tests and
carrier screening and the ability to bring the benefits of
noninvasive prenatal testing to as many patients as possible.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are
described more fully in the Company's filings with
the Securities and Exchange Commission, including without
limitation the Company's most recent Annual Report on Form 10-K and
other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Logo - http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-strengthens-executive-team-with-new-vice-president-of-sales-300250320.html
SOURCE Sequenom, Inc.